c-Abl kinase at the crossroads of healthy synaptic remodeling and synaptic dysfunction in neurodegenerative diseasesDaniela A.Gutiérrez，América Chandía-Cristi，María JoséYá?ez，Silvana Zanlungo，Alejandra R.álvarez237-243
The mechanism and relevant mediators associated with neuronal apoptosis and potential therapeutic targets in subarachnoid hemorrhageQi Tian，Sheng Liu，Shou-Meng Han，Wei Zhang，Xian-Yao Qin，Jun-Hui Chen，Cheng-Li Liu，Yu-Jia Guo，Ming-Chang Li244-252
Brain and spinal cord trauma: what we know about the therapeutic potential of insulin growth factor 1 gene therapyMaría Jose Bellini，Florencia Labombarda253-257
Functions and mechanisms of cytosolic phospholipase A2 in central nervous system traumaHao-Jie Zhang，Yi-Tuo Chen，Xin-Li Hu，Wan-Ta Cai，Xiang-Yang Wang，Wen-Fei Ni，Kai-Liang Zhou258-266
Microglia depletion as a therapeutic strategy: friend or foe in multiple sclerosis models?Victoria Sofia Berenice Wies Mancini，Anabella Ayelen Di Pietro，Laura Andrea Pasquini267-272
Cre-recombinase systems for induction of neuron-specific knockout models: a guide for biomedical researchersTetiana Shcholok，Eftekhar Eftekharpour273-279
Prenatal programing of motivated behaviors: can innate immunity prime behavior?Larisa Montalvo-Martínez，Gabriela Cruz-Carrillo，Roger Maldonado-Ruiz，Luis A.Trujillo-Villarreal，Eduardo A.Garza-Villarreal，Alberto Camacho-Morales280-283
Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative reviewFioravante Capone，Mariagrazia Rossi，Alessandro Cruciani，Francesco Motolese，Fabio Pilato，Vincenzo Di Lazzaro284-288
Simulating traumatic brain injury in vitro: developing high throughput models to test biomaterial based therapiesRaja Haseeb Basit，Jessica Wiseman，Farhana Chowdhury，Divya Maitreyi Chari289-292
Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's diseaseBaptiste Texier，Morgane Prime，Djamaa Atamena，Pascale Belenguer，Marion Szelechowski293-298
